Key Metrics
16.8
Heat Index-
Impact LevelMedium
-
Scope LevelGlobal
-
Last Update2025-11-04
Key Impacts
Positive Impacts (3)
Event Overview
The company's financial results indicate significant revenue and EBITDA growth, reflecting an expansion of its healthcare platform. Despite mixed earnings, the firm is increasing its global presence and aims to revolutionize access to care through new specialties and partnerships.
Collect Records
Hims & Hers Reports Q3 2025 Financial Results and Expands Healthcare Services
Hers Health Inc. reported its Q3 2025 financial results, highlighting a 49% year-over-year revenue growth and a 53% increase in EBITDA. The company is expanding its platform to be more personal and proactive, launching new specialties and partnerships. Hims & Hers is experiencing rapid global growth and aims to transform how the world accesses care. The company reported mixed earnings, missing diluted EPS estimates at $0.06 versus the expected $0.09, but beating revenue expectations with $598.9 million in sales compared to the anticipated $580.2 million. Hims updated its full-year revenue guidance to approximately $2.35 billion, from the previous range of $2.3 billion to $2.4 billion. The company plans to introduce comprehensive lab testing capabilities soon, supporting its upcoming longevity specialty and injectable testosterone offerings, both set for release next year.